ANDATOPICALSOLUTION
Approved
Apr 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
TAVABOROLE (tavaborole) by R-Pharm US is protein synthesis inhibitors [moa]. Approved for oxaborole antifungal [epc]. First approved in 2023.
Drug data last refreshed 20h ago
$0.0BPart D
Mechanism of Action
Protein Synthesis Inhibitors
Pharmacologic Class:
Oxaborole Antifungal
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Started Oct 2015
55 enrolled
OnychomycosisTinea Unguium
Company
Worked on TAVABOROLE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.